Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Curcumin (Turmeric Extract) in 500 mg capsules (manufactured by Karen Company, Iran) three times a day for three months. Intervention 2: Control group: Placebo (Mal
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The willingness to voluntarily participate in the study Diagnosis of polycystic ovary syndrome by a specialist physician in the mild to moderate phase Having impaired glucose tolerance (IGT) The consumer is just one of the metformin or clomiphene drug groups Age more than 18 years old BMI higher than 25 and less than 30 kg/m2
Exclusion criteria
Exclusion criteria: Change the type and dosage of the drug over the past month Congenital hormonal disorders, autoimmune diseases, cancer, inflammatory diseases, hyperthyroidism and hypothyroidism, infections, pregnancy or lactation in women, or use of contraceptive pills The use of multi-vitamin-mineral, omega-3, polyphenolic and antioxidant supplements, as well as the use of anticoagulants such as heparin and warfarin or aspirin, blood cholesterol-lowering drugs (statins), NSAIDs, such as ipobrofen, aspirin and diclofenac, Antihistamines, calcium channel antagonists such as nifedipine, anti-TNF drugs (infliximab, adalimumab and cinnura), glucocorticosteroids (cortisone, prednisolone) and spironolactone during in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Blood Sugar. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Fasting Insulin. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;PGC1-a gene expression. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: Real Time RT-PCR.;Sirt1 gene expression. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: Real Time RT-PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum GPx. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Serum SOD. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Serum Concentration of DHEA hormone. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Serum concentration of LH. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Serum Concentration of FSH hormone. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: laboratory kit.;Insulin resistance. Timepoint: At the beginning of the study (before the intervention) and the end of the study (3 months after the intervention). Method of measurement: Computing. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad Shidfar
Iran University of Medical Sciences
Outcome results
None listed